COVID-19 vaccines: ethical framework concerning human challenge studies.
Daniela CalinaThomas HartungAnca Oana DoceaDemetrios A SpandidosAlex M EgorovMichael I ShtilmanFelix CarvalhoAristidis TsatsakisPublished in: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences (2020)
One possibility to shorten the time required for the development of COVID-19 vaccines is to reduce clinical phases II and III by using human challenge studies through eliberate infection of healthy volunteers with SARS-CoV-2 after administration of the candidate vaccine. Accelerating the development of a COVID-19 vaccine even for a few weeks or months would have a great beneficial impact on public health by saving many lives.